Pulmonary hypertension epidemiology and demographics: Difference between revisions
No edit summary |
Rim Halaby (talk | contribs) |
||
| Line 19: | Line 19: | ||
===Age=== | ===Age=== | ||
Pulmonary | Pulmonary hypertension usually develops between the ages of 20 and 60, but it can occur at any age. | ||
===Gender=== | ===Gender=== | ||
'''Idiopathic pulmonary hypertension'''(IPAH) which is more prevalent in women (3x more common), was considered the most common type of Pulmonary arterial hypertension in a French registry. | '''Idiopathic pulmonary hypertension''' (IPAH) which is more prevalent in women (3x more common), was considered the most common type of Pulmonary arterial hypertension in a French registry. | ||
===Genetics=== | ===Genetics=== | ||
| Line 28: | Line 28: | ||
'''Familial PAH''' often results from a [[mutation]] in the bone morphogenic protein receptor-2 (BMPR2) and is inherited as an [[autosomal dominant]] disease with incomplete [[penetrance]] and anticipation. | '''Familial PAH''' often results from a [[mutation]] in the bone morphogenic protein receptor-2 (BMPR2) and is inherited as an [[autosomal dominant]] disease with incomplete [[penetrance]] and anticipation. | ||
=== | ===Association with Diseases=== | ||
*PAH is also associated with:<ref>ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension</ref> | *PAH is also associated with:<ref>ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension</ref> | ||
#[[Congenital heart disease]](30% of untreated) | #[[Congenital heart disease]](30% of untreated) | ||
#[[Connective tissue diseases]](12% of patients with scleroderma and | #[[Connective tissue diseases]](12% of patients with scleroderma and up to 21% of patients with rheumatoid arthritis) | ||
#[[HIV]] (0.5%) | #[[HIV]] (0.5%) | ||
#[[Portal hypertension]] (2-6%) | #[[Portal hypertension]] (2-6%) | ||
#[[Sickle cell disease]] (20 to 40%) | #[[Sickle cell disease]] (20 to 40%) | ||
#[[Systemic lupus erythematosus]] (4 to 14%) | #[[Systemic lupus erythematosus]] (4 to 14%) | ||
#[[Hemoglobinopathies]] | #[[Hemoglobinopathies]] | ||
#[[Myeloproliferative disorders]] | #[[Myeloproliferative disorders]] | ||
#Drugs and toxins | #Drugs and toxins | ||
*Diet pills such as [[Fen-Phen]] produced an annual incidence of 25-50 per million per year. | *Diet pills such as [[Fen-Phen]] produced an annual incidence of 25-50 per million per year. | ||
==References== | ==References== | ||
Revision as of 12:19, 29 August 2014
|
Pulmonary Hypertension Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pulmonary hypertension epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Pulmonary hypertension epidemiology and demographics |
|
Pulmonary hypertension epidemiology and demographics in the news |
|
Blogs on Pulmonary hypertension epidemiology and demographics |
|
Risk calculators and risk factors for Pulmonary hypertension epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ralph Matar
Overview
Pulmonary arterial hypertension has been considered as a disease of young women. The mean age of patients in the U.S. registry was 36 years and the overall female-to-male ratio was 1.7:1.[1]
Epidemiology and Demographics
Incidence
While previously considered a rare disease, the most recent evidence from a French registry suggests that the incidence of new cases of pulmonary arterial hypertension is 2-3 cases per million per year.
Prevalence
The prevalence is about 15 per million.
Age
Pulmonary hypertension usually develops between the ages of 20 and 60, but it can occur at any age.
Gender
Idiopathic pulmonary hypertension (IPAH) which is more prevalent in women (3x more common), was considered the most common type of Pulmonary arterial hypertension in a French registry.
Genetics
Familial PAH often results from a mutation in the bone morphogenic protein receptor-2 (BMPR2) and is inherited as an autosomal dominant disease with incomplete penetrance and anticipation.
Association with Diseases
- PAH is also associated with:[2]
- Congenital heart disease(30% of untreated)
- Connective tissue diseases(12% of patients with scleroderma and up to 21% of patients with rheumatoid arthritis)
- HIV (0.5%)
- Portal hypertension (2-6%)
- Sickle cell disease (20 to 40%)
- Systemic lupus erythematosus (4 to 14%)
- Hemoglobinopathies
- Myeloproliferative disorders
- Drugs and toxins
- Diet pills such as Fen-Phen produced an annual incidence of 25-50 per million per year.
References
- ↑ Rich, S.; Dantzker, DR.; Ayres, SM.; Bergofsky, EH.; Brundage, BH.; Detre, KM.; Fishman, AP.; Goldring, RM.; Groves, BM. (1987). "Primary pulmonary hypertension. A national prospective study". Ann Intern Med. 107 (2): 216–23. PMID 3605900. Unknown parameter
|month=ignored (help) - ↑ ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension